Rechallenge Strategy in Cancer Therapy

Area of Science:

• Oncology
• Cancer Therapeutics
• Pharmacology

Background:

• Drug resistance is a primary obstacle to achieving cures or long-term survival in systemic anticancer therapy.
• Clinical definitions often equate "drug resistant" with "progressive disease" after treatment initiation.
• Current clinical trial protocols typically halt treatment upon disease progression, limiting data on resistance reversibility.

Purpose of the Study:

• To review drug rechallenge and treatment continuation strategies beyond disease progression.
• To focus on chemotherapy, immunotherapy, and targeted therapy in major cancer types.
• To challenge the concept of permanent drug resistance by examining data on re-challenging previously resistant tumors.

Main Methods:

• Literature review of existing clinical trial data and scientific publications.
• Analysis of rechallenge strategies for chemotherapy, immune therapy, and targeted therapy.
• Focus on data relevant to cancer treatment continuation beyond progression.

Main Results:

• Drug rechallenge and treatment continuation beyond progression are emerging strategies, particularly for molecularly targeted agents and immunotherapy.
• Evidence suggests that resistance may not always be permanent, opening possibilities for re-treatment.
• The review synthesizes findings across various cancer types and therapeutic modalities.

Conclusions:

• Rechallenge strategies offer potential to improve outcomes for patients with progressive cancer.
• Further research and clinical trials are needed to fully elucidate the efficacy and optimal application of these strategies.
• Challenging the paradigm of permanent drug resistance is crucial for advancing cancer care.